EE200200372A - VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks - Google Patents
VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviksInfo
- Publication number
- EE200200372A EE200200372A EEP200200372A EEP200200372A EE200200372A EE 200200372 A EE200200372 A EE 200200372A EE P200200372 A EEP200200372 A EE P200200372A EE P200200372 A EEP200200372 A EE P200200372A EE 200200372 A EE200200372 A EE 200200372A
- Authority
- EE
- Estonia
- Prior art keywords
- vla
- autoimmune
- inflammatory
- treatment
- cell binding
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17326099P | 1999-12-28 | 1999-12-28 | |
PCT/IB2000/001893 WO2001051487A1 (en) | 1999-12-28 | 2000-12-15 | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200372A true EE200200372A (et) | 2003-12-15 |
Family
ID=22631221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200372A EE200200372A (et) | 1999-12-28 | 2000-12-15 | VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks |
Country Status (35)
Country | Link |
---|---|
US (4) | US20020049236A1 (cs) |
EP (1) | EP1244656A1 (cs) |
JP (1) | JP2003519697A (cs) |
KR (1) | KR20020067050A (cs) |
CN (1) | CN1413210A (cs) |
AP (1) | AP2002002565A0 (cs) |
AR (1) | AR029216A1 (cs) |
AU (1) | AU2018301A (cs) |
BG (1) | BG106867A (cs) |
BR (1) | BR0016818A (cs) |
CA (1) | CA2396087A1 (cs) |
CO (1) | CO5261616A1 (cs) |
CR (1) | CR6682A (cs) |
CZ (1) | CZ20022072A3 (cs) |
EA (1) | EA004673B1 (cs) |
EE (1) | EE200200372A (cs) |
GT (1) | GT200000226A (cs) |
HU (1) | HUP0203897A3 (cs) |
IL (1) | IL149758A0 (cs) |
IS (1) | IS6382A (cs) |
MA (1) | MA26861A1 (cs) |
NO (1) | NO20023085D0 (cs) |
NZ (1) | NZ518886A (cs) |
OA (1) | OA12126A (cs) |
PA (1) | PA8509301A1 (cs) |
PE (1) | PE20010987A1 (cs) |
PL (1) | PL357109A1 (cs) |
SK (1) | SK8692002A3 (cs) |
SV (1) | SV2002000246A (cs) |
TN (1) | TNSN00256A1 (cs) |
TR (1) | TR200201668T2 (cs) |
UY (1) | UY26512A1 (cs) |
WO (1) | WO2001051487A1 (cs) |
YU (1) | YU41202A (cs) |
ZA (1) | ZA200205142B (cs) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1244656A1 (en) * | 1999-12-28 | 2002-10-02 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
CN100471838C (zh) | 2000-12-28 | 2009-03-25 | 第一制药株式会社 | Vla-4抑制剂 |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
CA2518318A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
CN1826336B (zh) | 2003-07-24 | 2010-06-02 | 第一制药株式会社 | 环己烷羧酸类 |
US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
CA2555227A1 (en) * | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinone ureas as antagonists of .alpha.4 integrins |
CA2555594A1 (en) * | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica N.V. | Pyridazinones as antagonists of a4 integrins |
TW200610754A (en) * | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7414134B2 (en) * | 2004-10-12 | 2008-08-19 | Amgen Inc. | B1 bradykinin receptor antagonists |
US20070042049A1 (en) * | 2005-06-03 | 2007-02-22 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
WO2006133338A1 (en) * | 2005-06-07 | 2006-12-14 | The Trustees Of The University Of Pennesylvania | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN |
US8987306B2 (en) * | 2005-06-07 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold |
EP1961750B1 (en) | 2005-12-13 | 2013-09-18 | Daiichi Sankyo Company, Limited | Vla-4 inhibitory drug |
DK1984344T3 (da) * | 2005-12-29 | 2013-01-14 | Lexicon Pharmaceuticals Inc | Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf |
US20100150915A1 (en) | 2007-02-20 | 2010-06-17 | Stewart Edward J | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
US8012886B2 (en) * | 2007-03-07 | 2011-09-06 | Asm Assembly Materials Ltd | Leadframe treatment for enhancing adhesion of encapsulant thereto |
CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
PL3326645T3 (pl) | 2010-10-25 | 2020-09-21 | Biogen Ma Inc. | Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM |
US9340500B2 (en) | 2011-04-20 | 2016-05-17 | Shionogi & Co., Ltd. | Aromatic heterocyclic derivative having TRPV4-inhibiting activity |
US8778941B2 (en) | 2011-06-24 | 2014-07-15 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
PE20140868A1 (es) | 2011-06-24 | 2014-07-18 | Amgen Inc | Antagonistas trpm8 y su uso en tratamientos |
CN102268067A (zh) * | 2011-06-29 | 2011-12-07 | 河北师范大学 | 一种含ldv序列短肽的聚乙二醇化衍生物 |
EP2769223A1 (en) | 2011-10-17 | 2014-08-27 | Westfälische Wilhelms-Universität Münster | Assessment of pml risk and methods based thereon |
KR20190007106A (ko) | 2011-12-21 | 2019-01-21 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
BR112015004205B1 (pt) | 2012-08-28 | 2022-02-01 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto |
US20150202287A1 (en) | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
EP2981536B1 (en) | 2013-04-03 | 2017-06-14 | Janssen Sciences Ireland UC | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
ES2695182T3 (es) | 2013-05-17 | 2019-01-02 | Janssen Sciences Ireland Uc | Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B |
DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
WO2015059212A1 (en) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US20150216938A1 (en) | 2014-02-05 | 2015-08-06 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
MX2017000087A (es) * | 2014-06-30 | 2017-08-16 | Uab Res Found | Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer. |
EA201792069A1 (ru) | 2015-03-19 | 2018-04-30 | Новира Терапьютикс, Инк. | Производные азокана и азонана и способы лечения инфекций гепатита в |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CA3000197A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
JP2019511542A (ja) | 2016-04-15 | 2019-04-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合阻害剤を含む組み合わせ及び方法 |
MX2020009531A (es) | 2018-03-14 | 2020-10-05 | Janssen Sciences Ireland Unlimited Co | Regimen posologico del modulador del ensamblaje de la capside. |
EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
JP2022532526A (ja) | 2019-05-06 | 2022-07-15 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbv感染又はhbv誘導性疾患の処置において有用なアミド誘導体 |
WO2022162164A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5294713A (en) | 1991-08-23 | 1994-03-15 | Takeda Chemical Industries, Ltd. | 2-piperazinone compounds and their use |
WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
US5936065A (en) | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
AU2958195A (en) | 1994-06-29 | 1996-01-25 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
CA2193508A1 (en) | 1994-07-11 | 1996-01-25 | Eugene D. Thorsett | Inhibitors of leukocyte adhesion |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
WO1996040781A1 (en) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION |
EP0842195A1 (en) | 1995-07-06 | 1998-05-20 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
PL191082B1 (pl) * | 1996-07-25 | 2006-03-31 | Biogen | Inhibitor IIb/IIIa, sposób jego wytwarzania i jego zastosowanie |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647382A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
JP2002501537A (ja) | 1997-05-29 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としてのスルホンアミド類 |
EP1017382B1 (en) | 1997-05-29 | 2006-03-01 | Merck & Co., Inc. (a New Jersey corp.) | Biarylalkanoic acids as cell adhesion inhibitors |
EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterocyclic amides as cell adhesion inhibitors |
WO1998054207A1 (en) | 1997-05-30 | 1998-12-03 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
AU8163398A (en) | 1997-06-23 | 1999-01-04 | Pharmacia & Upjohn Company | Inhibitors of alpha4beta1mediated cell adhesion |
CN1265673A (zh) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 抑制由vla-4介导的白细胞粘着的二肽化合物 |
EP1001975A1 (en) | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
ATE327245T1 (de) | 1997-07-31 | 2006-06-15 | Elan Pharm Inc | Verbindungen mit einer 4-amino-phenylalaningruppe,die die vla-4 vermittelte adhäsion von leukozyten inhibieren |
AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
ZA986827B (en) | 1997-07-31 | 2000-05-02 | Athena Neurosciences Inc | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4. |
PL338506A1 (en) | 1997-07-31 | 2000-11-06 | Elan Pharm Inc | Compounds inhibiting adhesion of leucocytes occuring through the mediation of vla-4 |
CA2290748A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
BR9812111A (pt) | 1997-07-31 | 2000-07-18 | Elan Pharm Inc | Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4 |
KR100615760B1 (ko) | 1997-08-22 | 2006-08-25 | 에프. 호프만-라 로슈 아게 | 엔-알카노일페닐알라닌 유도체 |
PT1005445E (pt) | 1997-08-22 | 2004-09-30 | Hoffmann La Roche | Derivados de n-alcanoilfenilalanina |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
AU1361499A (en) | 1997-10-21 | 1999-05-10 | Merck & Co., Inc. | Azapeptide acids as cell adhesion inhibitors |
ES2268793T3 (es) * | 1997-10-31 | 2007-03-16 | Aventis Pharma Limited | Anilidas sustituidas. |
GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
AU1415099A (en) * | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
AU1411499A (en) | 1997-11-20 | 1999-06-15 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
WO1999026922A1 (en) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
DE69824037T2 (de) | 1997-11-24 | 2005-06-02 | Merck & Co., Inc. | Beta-alanin-derivate als zell-adhäsions-inhibitoren |
WO1999026615A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
AU747907B2 (en) * | 1997-12-23 | 2002-05-30 | Aventis Pharma Limited | Substituted beta-alanines |
US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
HUP0100336A3 (en) * | 1998-01-23 | 2002-11-28 | Novartis Ag | Vla-4 antagonists, pharmaceutical compositions comprising them and process for preparing them |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
DE69919334T2 (de) | 1998-02-26 | 2005-08-04 | Celltech Therapeutics Ltd., Slough | Phenylalaninderivate als inhibitoren von alpha4 integrinen |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
NZ507534A (en) | 1998-04-16 | 2002-02-01 | Texas Biotechnology Corp | N,N-disubstituted amide substituted propanoic acid derivatives useful for inhibiting the binding of intergrins to their receptors |
WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
EE04639B1 (et) | 1998-05-28 | 2006-06-15 | Biogen, Inc. | Raku adhesiooni pärssiv ühend ja seda sisaldav farmatseutiline kompositsioon |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
AU8059598A (en) | 1998-06-11 | 1999-12-30 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
CA2336625A1 (en) * | 1998-06-30 | 2000-01-06 | Louis Stanley Chupak | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
AU1915399A (en) | 1998-07-10 | 2000-02-01 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
EP1133484A2 (en) | 1998-07-23 | 2001-09-19 | AstraZeneca AB | Heterocyclic derivatives and their use as integrin inhibitors |
GB9916374D0 (en) | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
PL346248A1 (en) | 1998-08-26 | 2002-01-28 | Aventis Pharma Ltd | Aza-bicycles which modulate the inhibition of cell adhesion |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821406D0 (en) | 1998-10-01 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002532457A (ja) | 1998-12-14 | 2002-10-02 | アメリカン・ホーム・プロダクツ・コーポレイション | Vla−4により仲介される白血球接着を阻害する3,4−ジアミノ−3−シクロブテン−1,2−ジオン誘導体 |
GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
WO2000043369A1 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
IL143928A0 (en) | 1999-01-22 | 2002-04-21 | Elan Pharm Inc | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
EP1144364B1 (en) | 1999-01-22 | 2005-07-13 | Elan Pharmaceuticals, Inc. | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
EP1244656A1 (en) * | 1999-12-28 | 2002-10-02 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
-
2000
- 2000-12-15 EP EP00983429A patent/EP1244656A1/en not_active Withdrawn
- 2000-12-15 EE EEP200200372A patent/EE200200372A/xx unknown
- 2000-12-15 TR TR2002/01668T patent/TR200201668T2/xx unknown
- 2000-12-15 CA CA002396087A patent/CA2396087A1/en not_active Abandoned
- 2000-12-15 OA OA1200200193A patent/OA12126A/en unknown
- 2000-12-15 SK SK869-2002A patent/SK8692002A3/sk not_active Application Discontinuation
- 2000-12-15 PL PL00357109A patent/PL357109A1/xx not_active Application Discontinuation
- 2000-12-15 HU HU0203897A patent/HUP0203897A3/hu unknown
- 2000-12-15 EA EA200200619A patent/EA004673B1/ru not_active IP Right Cessation
- 2000-12-15 NZ NZ518886A patent/NZ518886A/en unknown
- 2000-12-15 CN CN00817813A patent/CN1413210A/zh active Pending
- 2000-12-15 JP JP2001551869A patent/JP2003519697A/ja not_active Withdrawn
- 2000-12-15 IL IL14975800A patent/IL149758A0/xx unknown
- 2000-12-15 AU AU20183/01A patent/AU2018301A/en not_active Abandoned
- 2000-12-15 WO PCT/IB2000/001893 patent/WO2001051487A1/en not_active Application Discontinuation
- 2000-12-15 CZ CZ20022072A patent/CZ20022072A3/cs unknown
- 2000-12-15 YU YU41202A patent/YU41202A/sh unknown
- 2000-12-15 AP APAP/P/2002/002565A patent/AP2002002565A0/en unknown
- 2000-12-15 KR KR1020027008400A patent/KR20020067050A/ko not_active Application Discontinuation
- 2000-12-15 BR BR0016818-1A patent/BR0016818A/pt not_active IP Right Cessation
- 2000-12-21 US US09/747,246 patent/US20020049236A1/en not_active Abandoned
- 2000-12-22 SV SV2000000246A patent/SV2002000246A/es unknown
- 2000-12-26 TN TNTNSN00256A patent/TNSN00256A1/fr unknown
- 2000-12-27 GT GT200000226A patent/GT200000226A/es unknown
- 2000-12-27 CO CO00097880A patent/CO5261616A1/es unknown
- 2000-12-27 AR ARP000106961A patent/AR029216A1/es not_active Application Discontinuation
- 2000-12-28 UY UY26512A patent/UY26512A1/es not_active Application Discontinuation
- 2000-12-28 PA PA20008509301A patent/PA8509301A1/es unknown
- 2000-12-28 PE PE2000001411A patent/PE20010987A1/es not_active Application Discontinuation
-
2002
- 2002-05-14 IS IS6382A patent/IS6382A/is unknown
- 2002-06-12 US US10/171,286 patent/US6667331B2/en not_active Expired - Fee Related
- 2002-06-12 US US10/170,289 patent/US6668527B2/en not_active Expired - Fee Related
- 2002-06-14 CR CR6682A patent/CR6682A/es not_active Application Discontinuation
- 2002-06-24 BG BG106867A patent/BG106867A/xx unknown
- 2002-06-24 MA MA26709A patent/MA26861A1/fr unknown
- 2002-06-26 NO NO20023085A patent/NO20023085D0/no not_active Application Discontinuation
- 2002-06-26 ZA ZA200205142A patent/ZA200205142B/en unknown
-
2003
- 2003-11-05 US US10/702,539 patent/US6903128B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200200372A (et) | VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks | |
EE200100480A (et) | Ksenoon kasutamiseks närvimürgistuste ravis | |
MA26771A1 (fr) | Benzoheterocycles et leur utilisation comme inhibiteurs de mek. | |
DE60142955D1 (de) | Batterieladeverfahren und batterieblock | |
FR2823209B1 (fr) | Nouvelles thiohydantoines et leur utilisation en therapeutique | |
ZA993777B (en) | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. | |
MA26348A1 (fr) | 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation | |
DE60221407D1 (de) | Speichersystem und Speichersubsystem | |
NO20021449D0 (no) | Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav | |
HK1109867A1 (en) | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | |
ATE258928T1 (de) | Respiratorisches syncytialvirus replikation inhibitoren | |
PT1326853E (pt) | Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7 | |
DE60035564D1 (de) | Batterieladevorrichtung | |
DE50005461D1 (de) | Zwei-batteriensystem | |
DE10081593T1 (de) | Tragbares Batterieladegerät | |
DE50010609D1 (de) | Sport-trainings-vorrichtung sowie sport-trainings-system | |
DE60038470D1 (de) | Sekundärbatterie | |
DE29903348U1 (de) | Rolleinrichtung | |
AU2003249645A8 (en) | Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases | |
DE50005631D1 (de) | Zwei-batteriensystem | |
DE60039018D1 (de) | Batterieladevorrichtung | |
PT946175E (pt) | Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais | |
IL155433A0 (en) | Treatment of t cell disorders | |
PT1214302E (pt) | 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao como inibidores de lipase | |
ITMI20001555A0 (it) | Procedimento e dispositivo di trattamento elettrochimico |